A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced $BRAF^{V600}$ mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

Melanoma research - ISSN 0960-8931-32:3 (2022) p. 183-191
    Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart NEYNS